A 35-year-old male with cystic fibrosis presents with chronic Pseudomonas aeruginosa lung colonization and recurrent pulmonary exacerbations. For chronic suppressive therapy and maintenance of lung function, which agent is the drug of choice?

Explanation

## Drug of Choice for Chronic P. aeruginosa Suppression in Cystic Fibrosis **Key Point:** Inhaled tobramycin is the gold standard for chronic suppressive therapy of P. aeruginosa in cystic fibrosis patients. It delivers high local lung concentrations, minimizes systemic toxicity, and reduces exacerbation frequency. ### Why Inhaled Tobramycin? **High-Yield:** Inhaled tobramycin (TOBI®) is FDA-approved and guideline-recommended for CF patients with chronic P. aeruginosa colonization because it: - Achieves very high sputum concentrations (>1000 µg/mL) with minimal systemic absorption - Reduces bacterial density in airways - Decreases exacerbation frequency and hospitalizations - Improves or stabilizes FEV~1~ - Minimizes nephrotoxicity and ototoxicity (systemic aminoglycoside toxicity) - Administered in alternating months (on 28 days, off 28 days) to prevent resistance **Clinical Pearl:** The inhaled route is preferred over systemic therapy for chronic suppression because it concentrates drug at the site of infection while avoiding systemic toxicity. This is unique to CF management. ### Comparison of Options for Chronic Suppression | Agent | Route | Role in CF P. aeruginosa | Limitation | | --- | --- | --- | --- | | **Inhaled tobramycin** | **Inhaled** | **Gold standard for chronic suppression** | **None — preferred agent** | | Meropenem | IV | Reserved for acute exacerbations requiring hospitalization | Systemic exposure; not suitable for chronic outpatient suppression | | Ciprofloxacin | Oral | May be used as adjunct or for mild exacerbations | Inferior to inhaled aminoglycosides for chronic suppression; resistance develops quickly | | Piperacillin-tazobactam | IV | Reserved for acute exacerbations requiring hospitalization | Systemic exposure; not suitable for chronic outpatient suppression | **Warning:** Do NOT confuse acute exacerbation management (which may require IV combination therapy) with chronic suppressive therapy (which uses inhaled tobramycin). The clinical context determines the regimen. ### Dosing and Schedule - **Inhaled tobramycin:** 300 mg (in 5 mL saline) nebulized twice daily for 28 days, then off for 28 days (alternating months) - Improves lung function and reduces hospitalizations when used this way **Mnemonic:** **CF-TOBI** = **C**ystic **F**ibrosis uses **TOBI** (tobramycin inhalation solution) for chronic suppression [cite:Harrison 21e Ch 143; Cystic Fibrosis Foundation Guidelines]